Nonalcoholic Steatohepatitis Therapeutics Market (Drug Type: Obeticholic Acid (OCA), Aramchol (Arachidyl Amido Cholanoic Acid), Saroglitazar, and Elafibranor)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Nonalcoholic Steatohepatitis Therapeutics market size was estimated at USD 10.9 billion in 2021 and is expected to surpass around USD 21.1 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 14.6% during the forecast period 2022 to 2030.

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified; however, obesity and insulin resistance are believed to play major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its functions.

NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years, up to 20% of patients with NASH develop cirrhosis of the liver, and 10% succumb from the disease.

Presently, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are considered the leading cause of liver disease in countries in the West. Hence, there is an urgent need of effective treatment options for these diseases. This is expected to propel the nonalcoholic steatohepatitis therapeutics market over the next years.

Report Scope of the Nonalcoholic Steatohepatitis Therapeutics Market

Surge in Prevalence of Non-alcoholic Steatohepatitis Disease Globally

Nonalcoholic steatohepatitis is a type of liver disease diagnosed in people who are non-alcoholic or consume alcohol in very low amount. Nonalcoholic steatohepatitis (NASH) is one of the commonly diagnosed liver diseases. The disease is also known as silent liver disease. Fat deposition in liver, along with inflammation is one of the significant conditions that occurs during the disease. The surge in the incidence rate of nonalcoholic steatohepatitis has increased the demand for therapeutics to treat the disease. Consequently, multiple drugs are being launched. These drugs aim to provide relief from the disease.

According to market analysts, the global nonalcoholic steatohepatitis therapeutics market is anticipated to witness double digit growth in the next few years. Increase in awareness among people about therapeutics is also a major factor boosting the growth of the market in various regions across the world. However, poor diagnostics and lack of proper diagnostic technique are projected to restrain the global market in the next few years.

Rise in Investments in Drug Research and Development by Pharmaceutical Companies to Drive Global Market

Increase in research & development investments by pharmaceutical companies has led to seamless integration or multifunctional outsourcing solutions for drug research & development from the early development phase through the late-stage design phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources necessary for product innovation, as pharma businesses face massive pressure to minimize operating expenses. Key pharmaceutical corporations are shifting to a simpler business strategy that primarily depends on outsourcing.

Majority of pharmaceutical companies outsource their testing facilities throughout research and development to increase profit margins, meet drug discovery timeframes, and save money.

Increase in Number of People with Diabetes and Obesity to Propel Global Market

The number of patients suffering from nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is high across the globe. However, the number increases in developed economies such as North America. This provides significant opportunities to companies and research centers looking to invest in the market. Moreover, the number of children suffering from obesity has nearly tripled in the past few years. This requires urgent treatment methods to keep a check and cure the disease in its initial stages.

People in the U.S. also suffer from high cholesterol levels. There is no exact cure for the disease; however, treatment is still being developed and worked upon. Moreover, advancements in technology and continuous efforts by research firms to develop a more effective treatment method to drive the global nonalcoholic steatohepatitis therapeutics market.

Impact of COVID-19 on Global Nonalcoholic Steatohepatitis Therapeutics Market

The etiology of COVID-19 liver injury can be related to various reasons, including virus-induced inflammatory responses, hepatic obstruction, hypoxia, and drug-induced liver problems. Coronavirus has been linked to hepatic damage and liver-related fatality in cirrhotic individuals. The impact of COVID-19 on health services has had a negative influence on the care of delivery and the prognosis of patients with chronic liver disease. Consequently, there has been a drop in the therapy, detection, and follow-up of individuals with liver problems, which has had a severe effect on the healthcare industry. Additionally, drug clinical trials have stalled since most corporations have postponed the launch of newest studies in various nations.

Elafibranor Reduces Liver Fat, Gains Preference for Treatment of NASH

The global nonalcoholic steatohepatitis therapeutics market has been segmented based on drug type into potential phase III candidates’ obeticholic acid (OCA), Aramchol, Saroglitazar, and Elafibranor. Moreover, the report provides a list of candidates in phase I and phase II clinical trials. Elafibranor is expected to account for a key share of the global market during the forecast period, followed by Obeticholic Acid (OCA). The Elafibranor segment is expected to grow at the highest CAGR from 2022 to 2031.

Elafibranor has the capability to reduce fat substance of liver and has demonstrated positive impact during phase 3 clinical trials. This progress of the clinical trial has helped in the likelihood of commercialization of Elafibranor. Elafibranor has better prospects in the market, as there is no medicine available for the treatment of NASH.

Cost-cutting Pressure from Regulatory Bodies to Restrain Market Growth

Governments in both rich and emerging economies are advocating cost-cutting initiatives such as lowering prescription coverage costs and increasing the usage of generic medications. Governments, insurers, and individuals are putting substantial cost-cutting pressure on drug makers globally. This leads to increase in medication acceptance in developing countries, where there is a considerable need of low-cost treatments. This, however, has a negative effect on the performance of various pharmaceutical businesses. This trend is likely to continue during the forecast period, owing to the ongoing demand from insurers and lowering of pharma pricing by personal & corporate payers due to worries about providing more innovative drugs to treat prevalent ailments.

Regional Outlook of Global Nonalcoholic Steatohepatitis Therapeutics Market

In terms of region, the global nonalcoholic steatohepatitis therapeutics market has been segmented into North America, Asia Pacific, Europe, Latin America, Middle East & Africa. North America dominated the global market, accounting for key share in 2021.

North America is significantly affected by NASH due to rise in population suffering from diabetes and obesity. Moreover, prevailing cases of high cholesterol and changes in lifestyle make North America an attractive market for future development and growth.

In Europe, countries such as Italy, Spain, Germany, the U.K., and France are the main areas with high prevalence of NASH. These countries are likely to be highly lucrative markets for nonalcoholic steatohepatitis therapeutics.

Analysis of Key Players in Global Nonalcoholic Steatohepatitis Therapeutics Market

This report profiles key players in the global nonalcoholic steatohepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nonalcoholic steatohepatitis therapeutics market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global nonalcoholic steatohepatitis therapeutics market are Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd., among others.

The report on the global nonalcoholic steatohepatitis therapeutics market discusses individual strategies, followed by company profiles of manufacturers of the nonalcoholic steatohepatitis therapeutics market products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global nonalcoholic steatohepatitis therapeutics market.

Key Developments in Global Nonalcoholic Steatohepatitis Therapeutics Market

Key players in the global nonalcoholic steatohepatitis therapeutics market are growing their market presence by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market position across the world. Key developments in the global nonalcoholic steatohepatitis therapeutics market include:

• In January 2019, Genfit took the first step toward making this test available, as it had signed a licensing agreement with LabCorp, the leading drug development and NASH clinical trial company, to expand the access to NIS4 in the global clinical research community

Some of the prominent players in the Nonalcoholic Steatohepatitis Therapeutics Market include:

• AstraZeneca plc
• Intercept Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd.
• GENFIT SA
• Gilead Sciences, Inc.
• Zydus Cadila
• Immuron Ltd.
• Conatus Pharmaceuticals
• Tobira Therapeutics, Inc.
• Other prominent players

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Nonalcoholic Steatohepatitis Therapeutics market

• Drug Type
• Obeticholic Acid (OCA)
• Aramchol (Arachidyl Amido Cholanoic Acid)
• Saroglitazar
• Elafibranor

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Nonalcoholic Steatohepatitis Therapeutics industry analysis from 2022 to 2030 to identify the prevailing Nonalcoholic Steatohepatitis Therapeutics industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Nonalcoholic Steatohepatitis Therapeutics industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Nonalcoholic Steatohepatitis Therapeutics industry trends, key players, market segments, application areas, and market growth strategies.